| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5528060 | Leukemia Research Reports | 2017 | 5 Pages |
Abstract
Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals.Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104).These results support the efficacy of AZA in AML in the elderly in any line of treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
António Almeida, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, Ricardo Pinto,